Grifols, a Spanish pharmaceutical manufacturer, announced on Tuesday that it has approved the IPO of its biopharmaceutical business in the U.S.
Grifols, known for producing medications from blood plasma, plans to IPO a minority stake in the biopharmaceutical business. The parent company will remain listed on the stock exchange in Spain and retain the majority of the American company.
“This transaction reinforces Grifols’ self-sufficiency vision by creating the first and only player that does not depend on plasma, manufacturing, or sourcing outside of the United States,” stated Grifols.
Selling the stake through an IPO would raise capital to strengthen the balance sheet, reduce debt, and support investments in key markets, the company added.
In February, Grifols announced expectations of over a quarter increase in core earnings by 2026 and plans to continue reducing debt after more than doubling profits in 2025.
The group will continue to expand its plasma and diagnostic activities in other key markets, it stated on Tuesday.
